A phase II trial of combination therapy with arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) arising from MDS.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Sekeres, MA; Maciejewski, JP; Erba, HP; Sobecks, R; Advani, A; Nichols, J; Chan, J; Kalaycio, M

Published Date

  • November 16, 2006

Published In

Volume / Issue

  • 108 / 11

Start / End Page

  • 754A - 754A

Published By

Pages

  • 1

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 48th Annual Meeting of the American-Society-of-Hematology

Conference Location

  • Orlando, FL

Conference Start Date

  • December 9, 2006

Conference End Date

  • December 12, 2006